Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The cannabinoid-based therapeutics market was valued at USD 6.50 Billion in 2025 and is projected to reach USD 30.71 Billion by 2035, growing at a CAGR of 16.80%. Growth is supported by the burden of treatment-resistant epilepsy, unmet need in chronic pain, regulatory acceptance of pharmaceutical-grade cannabidiol medicines, and expanding access to prescription cannabinoids across Europe and North America.

Patent activity spans cannabidiol medicines for rare epilepsies, cannabinoid receptor modulators for pain and inflammation, biosynthetic production of rare cannabinoids, oromucosal, inhaled and transdermal delivery systems, and standardised plant extracts with defined cannabinoid ratios. Regulatory validation came with the FDA approval of a plant-derived cannabidiol solution in 2018 and its European authorisation in 2019, and these decisions have encouraged developers to file on formulations, synthetic analogues and manufacturing routes that reduce dependence on cultivated plant material.

This Cannabinoid-Based Therapeutics Patent Landscape Analysis Report provides a structured view of patent filing trends, leading assignees, jurisdictions, technology clusters and competitive positioning across cannabinoid medicines, receptor modulators, production methods and delivery systems.

Executive Snapshot

  • Global cannabinoid-based therapeutics market valued at USD 6.50 Billion in 2025
  • Market projected to reach USD 30.71 Billion by 2035
  • Expected CAGR of 16.80% during 2026 - 2035
  • Approximately 5,000+ patent families analysed across the landscape
  • 310+ cannabinoid-based therapeutics patents were granted in 2025
  • Leading jurisdictions include the United States, Europe, and China
  • 3,500+ cannabinoid-based therapeutics patents are associated with the United States
  • Major innovation areas include cannabidiol medicines for treatment-resistant epilepsy, cannabinoid receptor modulators for pain and inflammation, biosynthetic production of rare cannabinoids, and oromucosal and inhaled delivery of cannabinoid medicines
  • Top assignees include Jazz Pharmaceuticals, Canopy Growth, Tilray, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals
  • The cannabinoid-based therapeutics market is experiencing strong growth, driven by treatment-resistant epilepsy, chronic pain with limited alternatives to opioids, and regulatory acceptance of pharmaceutical-grade cannabinoid medicines. Epidiolex, approved by the FDA in 2018 for seizures in Lennox-Gastaut and Dravet syndromes, showed that a standardised cannabidiol medicine can clear full regulatory review and reach prescribers at scale.

  • Patent activity is accelerating, with 310+ cannabinoid-based therapeutics patents granted in 2025, reflecting strong innovation momentum in cannabidiol medicines for treatment-resistant epilepsy, cannabinoid receptor modulators for pain and inflammation, biosynthetic production of rare cannabinoids, and oromucosal and inhaled delivery of cannabinoid medicines.

  • Top assignees in the cannabinoid-based therapeutics patent landscape include Jazz Pharmaceuticals, Canopy Growth, Tilray, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, with the United States, Europe, and China as the dominant patent jurisdictions.

Cannabinoid-Based Therapeutics Market Size, Growth Trends, and Industry Outlook

Cannabinoid medicines have moved from folk and compassionate use to a regulated pharmaceutical category with approved products, controlled clinical trials and defined dosing. Treatment-resistant epilepsy, spasticity in multiple sclerosis, chemotherapy-induced nausea and chronic pain generate most of the prescribing demand, and interest is widening into anxiety, sleep disorders, inflammatory skin conditions and neuropsychiatric disease. Patients and physicians look for standardised composition, predictable dosing and safety data that unregulated products rarely provide. Developers compete on purified molecules, synthetic analogues, receptor-selective compounds and delivery systems that control onset and duration. Evolving national frameworks for medical access, together with hemp legalisation in the United States in 2018, have widened the supply base for raw material.

Market growth is driven by regulatory acceptance of standardised cannabidiol medicines, which gives prescribers an approved option in rare epilepsies and encourages payers to reimburse cannabinoid therapy. About 50 million people live with epilepsy worldwide according to the World Health Organization, and roughly one third do not achieve seizure control with existing medicines, which defines a large treatment-resistant population. The FDA approved Epidiolex in 2018 and the European Medicines Agency authorised it in 2019, giving the category its first approvals for a plant-derived cannabidiol medicine. Chronic pain adds further demand, with about one in five adults in the United States reporting it in national surveys.

A global epilepsy population of about 50 million, with one third resistant to current medicines, indicates a patient pool that rare-disease approvals have only partly reached, so new formulations and indications still have room to grow. The 2018 and 2019 approvals of a cannabidiol solution show that regulators will accept botanical-derived actives made under controlled manufacturing, which lowers perceived regulatory risk for later developers and supports investment in synthetic and biosynthetic routes. Roughly one in five United States adults reporting chronic pain signals demand for alternatives to opioids, although safety signals such as liver enzyme elevation and sedation shape dosing and label claims.

Total Number of Patents for Cannabinoid-Based Therapeutics

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cannabinoid-Based Therapeutics Patent Filing Trends and Innovation Activity

Filing intensity in cannabinoid-based therapeutics follows commercial investment closely. The 2021 acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals consolidated one of the deepest botanical drug portfolios under a single owner, and the commercial success of Epidiolex encouraged other developers to file on purified cannabidiol formulations, dosing regimens and new indications. Cultivation companies such as Canopy Growth and Tilray broadened filings into extraction, formulation and inhaled delivery as medical programmes expanded in Canada and Germany. Biotechnology firms add filings on yeast and bacterial production of rare cannabinoids, where cost and purity matter more than plant yield.

More than 5,000 patent families related to cannabinoid-based therapeutics were identified across the landscape. Filing peaked between roughly 2019 and 2023, when applications on cannabidiol formulations, receptor modulators and biosynthetic production expanded after regulatory approvals and the opening of medical access in several countries. Growth has been steady rather than abrupt, with annual publication counts rising through most of the last decade. The largest clusters cover cannabidiol medicines for treatment-resistant epilepsy, cannabinoid receptor modulators for pain and inflammation, biosynthetic production of rare cannabinoids, and oromucosal and inhaled delivery of cannabinoid medicines, while topical and transdermal systems and standardised full-spectrum plant extracts form a smaller but expanding second tier.

The alignment between approvals of cannabidiol medicines, rising prescribing in epilepsy and pain, and the expansion of filings on formulations, receptor modulators and biosynthesis shows that clinical and regulatory validation is feeding directly into patent coverage across the cannabinoid value chain.

Scope of the Cannabinoid-Based Therapeutics Patent Landscape Analysis Report

This report analyses patent activity and market trends associated with cannabinoid-based therapeutics across the United States, Europe, China, Japan, South Korea, India and international filings made through the World Intellectual Property Organization (WIPO). Coverage includes cannabinoid molecules, plant extracts, receptor modulators, production methods and delivery systems developed for medical use, drawn from national offices and regional authorities. Market context reflects the use of these medicines in Hospitals, Specialty Neurology and Pain Clinics, Retail and Online Pharmacies, Home Care Patients and Academic and Research Institutes, linking patent coverage to prescribing demand in each region.

The scope includes cannabidiol, tetrahydrocannabinol and synthetic analogues, rare and minor cannabinoids, cannabinoid receptor modulators and full-spectrum plant extracts as cannabinoid types. Therapeutic areas covered are neurology and epilepsy, pain and inflammation, oncology supportive care, psychiatric disorders, and dermatology and other conditions. Dosage forms comprise oral solutions and capsules, oromucosal sprays, inhaled formulations, topical and transdermal systems, and injectable formulations. Patents are further grouped by technology cluster to show where innovation concentrates.

The analysis includes patent activity from specialty pharmaceutical companies with approved cannabinoid medicines, licensed cannabis producers that supply medical products, and biotechnology firms developing receptor modulators and fermentation-based production. Academic medical centres, university research groups and clinical investigators that file on cannabinoid pharmacology, formulation science and biosynthetic pathways are also covered, together with hospital-affiliated teams that patent dosing and treatment methods. Suppliers of extraction equipment, inhalation devices and transdermal delivery components are included where their filings relate to cannabinoid-based therapeutics.

The report will cover the following sections in detail:

Analysis by Cannabinoid Type

  • Cannabidiol
  • Tetrahydrocannabinol and Synthetic Analogues
  • Rare and Minor Cannabinoids
  • Cannabinoid Receptor Modulators
  • Full-Spectrum Plant Extracts

Analysis by Therapeutic Area

  • Neurology and Epilepsy
  • Pain and Inflammation
  • Oncology Supportive Care
  • Psychiatric Disorders
  • Dermatology and Other Conditions

Analysis by Dosage Form

  • Oral Solutions and Capsules
  • Oromucosal Sprays
  • Inhaled Formulations
  • Topical and Transdermal Systems
  • Injectable Formulations

Global Cannabinoid-Based Therapeutics Patent Landscape Analysis

Cannabinoid-Based Therapeutics Patent Filing Trend Analysis

The evolution of patent filings in cannabinoid-based therapeutics starts with synthetic dronabinol and nabilone in the 1980s, followed by botanical drug filings on plant extracts and oromucosal sprays in the 2000s. Discovery of the body's cannabinoid receptors drove a wave of medicinal chemistry filings on selective modulators, while the 2018 approval of a purified cannabidiol solution shifted attention to formulation, dosing and new indications. Since about 2018, filings on biosynthetic production, rare cannabinoids and transdermal delivery have grown fastest. Annual grants of more than 310 patents in 2025 indicate a large base of enforceable rights and a continuing pipeline of new applications.

Patent filings increased at an estimated annual growth rate of approximately 11% between 2020 and 2024. Biosynthetic production and rare cannabinoid applications grew fastest, supported by falling fermentation costs and interest in compounds such as cannabigerol and cannabichromene. Receptor modulator filings expanded more steadily, while filings on cannabidiol formulations for epilepsy remained comparatively stable after the first approvals. Applicants also widened claims to cover dosing regimens, drug interactions and manufacturing controls, since process and use claims are often the most defensible protection for naturally occurring molecules.

Leading Companies and Assignee Analysis in the Cannabinoid-Based Therapeutics Patent Landscape

Among the players with cannabinoid-based therapeutics patent families, new entrants have been identified, which can be either established companies or startups developing novel technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Jazz Pharmaceuticals

Jazz Pharmaceuticals holds the most commercially advanced portfolio in cannabinoid-based therapeutics, built largely through its 2021 acquisition of GW Pharmaceuticals. Its Epidiolex oral solution of plant-derived cannabidiol was approved by the FDA in 2018 for Lennox-Gastaut and Dravet syndromes, extended to seizures linked to tuberous sclerosis complex in 2020, and authorised in Europe in 2019. The portfolio also covers the nabiximols oromucosal spray used for spasticity in multiple sclerosis, which is marketed in a number of countries outside the United States. Its intellectual property strategy combines formulation, dosing and indication claims with protection of cultivation and extraction know-how for botanical drug substances. Commercially, the company is positioned as the reference point for regulated cannabinoid medicines in neurology, with prescriber familiarity and payer coverage that smaller developers lack.

Canopy Growth

Canopy Growth is a Canadian cannabis company whose patent filings span cannabinoid formulations, extraction and purification methods, vaporisation devices and delivery technologies. Its medical offering in Canada and Europe, together with the Storz and Bickel vaporiser business that supplies inhalation devices certified as medical devices in Europe, gives it a visible position in inhaled cannabinoid delivery. The company has also filed on fast-onset and water-soluble formats and on cultivar-linked cannabinoid profiles. Regulatory status sits mainly within national medical cannabis and device frameworks rather than centrally approved drug dossiers, so products reach patients through licensed medical channels. Its intellectual property strategy leans on formulation and device claims, while commercial positioning rests on brand recognition and licensed cultivation capacity.

Other companies include Tilray, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals.

The leading assignees, Jazz Pharmaceuticals, Canopy Growth, Tilray, Corbus Pharmaceuticals and Zynerba Pharmaceuticals, hold a limited share of analysed patent families, which indicates a fragmented landscape with many small holders. Jazz Pharmaceuticals maintains deep coverage in cannabidiol medicines and oromucosal delivery, while Canopy Growth files on extraction, formulation and vaporisation. Tilray protects cannabinoid formulations and medical product forms, Corbus Pharmaceuticals concentrates on receptor-selective modulators for inflammatory and fibrotic disease, and Zynerba Pharmaceuticals protects transdermal cannabidiol gel systems. A long tail of universities, biotechnology firms and small pharmaceutical companies adds specialised claims on production, receptor pharmacology and delivery.

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Geographic Analysis of Cannabinoid-Based Therapeutics Patent Activity

The report assesses patent activity across major jurisdictions, including:

  • United States
  • Europe
  • China
  • Japan
  • South Korea
  • India
  • International and WIPO filings

The United States is the largest single jurisdiction for cannabinoid-based therapeutics, reflecting the size of its pharmaceutical market, the 2018 approval of a cannabidiol medicine and the concentration of venture-funded developers. Europe follows through European Patent Office filings and national validations, supported by the 2019 authorisation of a cannabidiol medicine and long experience with prescription nabiximols in several countries. China contributes growing activity because of its large hemp industry, extraction capacity and academic research on cannabinoid pharmacology. Japan, South Korea and India show smaller volumes shaped by cautious access rules for cannabis-derived medicines, while WIPO filings show which families applicants intend to take into several markets at once.

Global Cannabinoid-Based Therapeutics Patents - Country-wise Analysis for Key Players

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Cannabinoid-Based Therapeutics Technology Segmentation and Innovation Areas

The patent landscape is segmented by the technology categories most closely associated with cannabinoid-based therapeutics, which include:

  • Cannabidiol medicines for epilepsy
  • Cannabinoid receptor modulators for pain
  • Biosynthetic production of rare cannabinoids
  • Oromucosal and inhaled delivery systems
  • Topical and transdermal cannabinoid systems

Among these, cannabidiol medicines for epilepsy and related neurological conditions account for the largest share of recent patent activity. Applicants are filing on purified and lipid-based formulations, dosing regimens used alongside other anti-seizure medicines, crystalline forms, and manufacturing controls that limit tetrahydrocannabinol content. Growth in this cluster has been supported by the clinical results and approvals of 2018 and 2019, and the major assignees maintain active programmes in neurology alongside newer work in receptor modulators and biosynthetic production.

Competitive Landscape and Emerging Trends in the Cannabinoid-Based Therapeutics Market

The cannabinoid-based therapeutics market remains fragmented, shaped by one pharmaceutical leader with approved products and a wide field of cultivators, specialty developers and biotechnology start-ups. Competition is split between regulated drug developers that run clinical trials and licensed producers that supply medical cannabis products under national frameworks. Patent filings from newer entrants, particularly in fermentation-based production and receptor-selective compounds, show that product design and supply chains are still unsettled, and positions in formulation and delivery will influence who captures prescription revenue as access widens.

Companies are focusing on:

  • Purified cannabidiol formulations
  • Biosynthetic cannabinoid production
  • Rare cannabinoid drug candidates
  • Receptor-selective modulators
  • Oromucosal and inhaled delivery
  • Transdermal systems for localised therapy
  • Dosing regimens and interaction management

Emerging innovation themes include fermentation platforms that produce cannabigerol and other rare cannabinoids at pharmaceutical purity, peripherally restricted receptor modulators that avoid central psychoactive effects, and cannabinoid combinations aimed at anxiety, sleep and post-traumatic stress. Interest is growing in transdermal and inhaled systems with faster onset for breakthrough pain, and in water-soluble and lipid-based formulations that improve bioavailability, which is low for oral cannabinoids. Developers are also exploring cannabinoid therapy for inflammatory skin conditions and fibrotic disease, supported by precision dosing and standardised plant extracts.

Strategic Insights from the Cannabinoid-Based Therapeutics Patent Landscape

The patent landscape for cannabinoid-based therapeutics maps how innovation is distributed across cannabinoid types, therapeutic areas and dosage forms in more than 5,000 patent families, and it identifies the assignees and jurisdictions where protection is concentrated. Filings in cannabidiol medicines, receptor modulators and biosynthesis show where capital is being directed, while mature formulation families indicate where freedom to operate depends on expiry timelines. Together, the findings give pharmaceutical companies, producers, investors and health systems a structured view of competitive positions.

The landscape provides actionable intelligence for the following nine uses:

  • Intellectual property strategy
  • Research and development prioritisation
  • Competitive benchmarking of cannabinoid portfolios
  • Technology scouting in biosynthetic production
  • Licensing evaluation for formulation technologies
  • Partnership assessment with receptor specialists
  • Investment analysis of cannabinoid developers
  • Market entry planning by jurisdiction
  • Portfolio expansion across therapeutic areas

Research Methodology for the Cannabinoid-Based Therapeutics Patent Landscape Analysis

Patent research was conducted across major patent databases, including national and regional office records and international filings published under the Patent Cooperation Treaty. Search strategies combined Cooperative Patent Classification codes for cannabinoid compounds, plant extracts and pharmaceutical preparations with keyword queries on cannabinoid types, receptor targets, production methods and dosage forms. Records were gathered through the latest complete publication period, and equivalent filings were consolidated into patent families so that each invention was counted once.

Screening removed duplicate families and filings with no relevance to cannabinoid-based therapeutics. Remaining records were reviewed and classified by technology cluster, cannabinoid type, therapeutic area, dosage form, assignee and jurisdiction. Assignee names were standardised so that subsidiaries and name variants were attributed to a single owner, and legal status was used to separate granted patents from pending applications.

Market analysis supported the interpretation of patent trends through review of regulatory approvals, clinical trial publications, company disclosures and prescribing data. Patent activity was compared with approval timelines and commercial launches to show how innovation tracks demand. Findings were cross-checked across sources, and analyst estimates are described as approximate where exact counts were not available.

Related Reports

Cannabinoid Market

Medical Cannabis Market

Postoperative Pain Therapeutics Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Frequently Asked Questions About This Report

EMR's Cannabinoid-Based Therapeutics Patent Landscape Analysis provides a comprehensive assessment of patent filings, innovation clusters, assignee portfolios, and geographic filing patterns across the cannabinoid-based therapeutics landscape. The report identifies 5,000+ patent families, evaluates leading jurisdictions including the United States, Europe, and China, and profiles the top assignees by portfolio size.

The global cannabinoid-based therapeutics market was valued at USD 6.50 Billion in 2025. The market is projected to reach USD 30.71 Billion by 2035, expanding at a CAGR of 16.80% during 2026 - 2035.

The report analyses approximately 5,000+ patent families related to cannabinoid-based therapeutics. These include filings from the United States, Europe, China, and international WIPO filings.

Key companies operating within the landscape include Jazz Pharmaceuticals, Canopy Growth, Tilray, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, among others. These organisations collectively account for a significant portion of patent activity analysed in this report.

The report evaluates patent activity across the United States, Europe, China, Japan, South Korea, India, and international WIPO filings. The United States is the largest single jurisdiction for cannabinoid-based therapeutics, with 3,500+ patents associated with it across the 5,000+ patent families analysed.

Yes. The report scope can be customised based on geography, technology segment, assignee selection, time period, or specific innovation cluster focus. Readers can contact the EMR team to scope a customised study, such as a tailored patent landscape focused on particular cannabinoid types, delivery routes or assignees in cannabinoid-based therapeutics.

Patent landscape analysis helps organisations understand innovation trends, competitive activity, technology whitespace, and IP risk across a defined domain. For cannabinoid-based therapeutics, this report supports strategic decisions in R&D prioritisation, licensing evaluation, competitive benchmarking, and market entry planning.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Analysis by Cannabinoid Type

  • Cannabidiol
  • Tetrahydrocannabinol and Synthetic Analogues
  • Rare and Minor Cannabinoids
  • Cannabinoid Receptor Modulators
  • Full-Spectrum Plant Extracts

Analysis by Therapeutic AreaAnalysis by Therapeutic Area

  • Neurology and Epilepsy
  • Pain and Inflammation
  • Oncology Supportive Care
  • Psychiatric Disorders
  • Dermatology and Other Conditions

Analysis by Dosage Form

  • Oral Solutions and Capsules
  • Oromucosal Sprays
  • Inhaled Formulations
  • Topical and Transdermal Systems
  • Injectable Formulations

Analysis by End User

  • Hospitals
  • Specialty Neurology and Pain Clinics
  • Retail and Online Pharmacies
  • Home Care Patients
  • Academic and Research Institutes

Key Players Mentioned

  • Jazz Pharmaceuticals
  • Canopy Growth
  • Tilray
  • Corbus Pharmaceuticals
  • Zynerba Pharmaceuticals

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Mini Report

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us